Parallel Session: NAFLD and Non-Alcoholic Steatohepatitis- Clinical

Watch this live session to see some the top research in NAFLD and Non-Alcoholic Steatohepatitis. Content will only be aired on this date, at this time. Don't miss it!

• Safety and Efficacy of Tropifexor in Patients with Fibrotic NonAlcoholic Steatohepatitis:48 Week Results from Part C of Phase 2 Flight-FXR Study
  Presenting Author Arun Sanyal
• Characteristic Gene Expression Patterns in Whole Liver Tissue Associated with Distinct States of NAFLD
  Presenting Author Sonu Subudhi
• Dietary Risks for Liver Related Mortality Among NonAlcoholic Fatty Liver Disease (NAFLD): Data From the Global Burden of Disease (GBD) 2017
  Presenting Author James M Paik
• Treament with Growth Hormone Releasing Hormone Analog Reduces VEGFA, TGFβ1, and CSF1 Mechanisms of Tesamorelin Effect in NonAlcoholic Fatty Liver Disease
  Presenting Author Lindsay Fourman
• Onset of Obesity-Related Pediatric Nonalcoholic Fatty Liver Disease (PNAFLD) During Prepubertal Growth Exacerbates Hepatic Inflammation and Mitochondrial DNA Depletion to Accelerate Liver Injury
  Presenting Author Preeti Viswanathan
• HIV-Infected Persons with Hepatic Steatosis have a Unique Plasma Lipidome
  Presenting Author Curtis Gabriel